VAERS reports by lot

Pfizer COVID-19 lot EN2613: VAERS reports

38 VAERS reports list lot EN2613 as a Pfizer COVID-19 vaccine, received between 2021-03-17 and 2022-07-18. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
38
Reports
18%
Marked serious
3
With a death outcome
13
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)3923%
Neurological2615%
Gastrointestinal2112%
Musculoskeletal2112%
Cardiac / Cardiovascular1911%
Respiratory1710%
Dermatological (non-injection-site)106%
Allergic / Anaphylactic85%
Injection-site / Local reaction53%
Psychiatric / Neuropsychiatric32%
Thrombotic / Hematological21%
Autoimmune / Immune-mediated11%

Where reports came from

U.S. state of the reporter, where given (top 12).

Florida5
California4
Ohio3
Michigan2
Indiana2
Pennsylvania2
New Mexico2
Texas2
Washington1
Kentucky1
New York1
Oregon1

Reports by month received

2021-0310
2021-045
2021-052
2021-062
2021-072
2021-081
2021-101
2021-115
2022-014
2022-022
2022-032
2022-041
2022-071

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.